Obesity Discussion Forums - View Single Post - Obesity Presents New Market Opportunities for Pharmaceutical Companies

Obesity Discussion · 04-02-06, 02:24 AM

Obesity Presents New Market Opportunities for Pharmaceutical Companies
3/31/2006 11:45:00 AM EST
Research and Markets (http://www.researchandmarkets.com/reports/c31682) has announced the addition of Obesity Drug Discovery: Success and Challenges for a New Pharmaceutical Market to their offering.

Business Implications

-- The prevalence of obesity has increased dramatically in the last ten years, prompting the Centers for Disease Control and Prevention to describe obesity as an epidemic. Obesity increases predisposition to various diseases, including diabetes, cardiovascular diseases, and cancer. In 2004, the United States Health and Human Services declared obesity to be a disease, creating important changes to Medicare and health care reimbursement policy for obesity-related therapies.

-- Obesity has increasingly become the focus of major pharmaceutical companies as they recognize the potential for a new blockbuster market. Rimonabant, a drug that regulates appetite, is in Phase III clinical trials. Companies are also forming high-value alliances, including target and lead identification deals, with biotech companies for obesity drug discovery.

-- Research into the causes of obesity has identified many potential targets and pathways that could be exploited to create novel therapies. New investigational obesity drugs and drug targets can be generally categorized into those that regulate appetite, lipid metabolism, and adipocytes or their signals. Obesity research is still in its infancy, and researchers are likely to identify many new potential targets and therapeutic approaches.

-- Because obesity therapy is a preventive therapy for otherwise outwardly healthy people, patients and regulatory agencies will not tolerate unacceptable medium-to-long-term side effects. Companies must develop therapies with side effects that are not worse than the obesity-related comorbidities the drugs are trying to prevent. Another challenge for long-term obesity therapy is simply to overcome the evolutionary selection of multiple physiological and metabolic responses that favor appetite and fat storage.

In recent years, obesity has become a major health problem for many postindustrial societies, so much so that in 2004, the United States Health and Human Services declared obesity to be a disease. Obesity poses a major health risk because it greatly increases the risk of comorbidities such as diabetes, cardiovascular diseases, arthritis, and cancer. Recognizing the potential for a new blockbuster market, major pharmaceutical companies have increasingly focused on obesity and its causes, in the process identifying many potential targets and pathways that could be exploited to create novel therapies. Studies on the molecular mechanisms involved in obesity are revealing a complex set of pathways, feedback loops, hormones, and metabolites that integrate multiple physiological systems in the brain, gastrointestinal system, endocrine system, and metabolic systems. The challenge for obesity drug discovery is that drugs must compete against powerful physiological and behavioral factors that have been selected by evolution to favor feeding and energy storage.

In this Decision Resources report, we provide a detailed discussion of the mechanics of obesity and its comorbidities, as well as the targets and pathways identified as points of intervention by investigational obesity drugs. We will also examine directions being pursued in obesity research and development and corporate alliances and activities in the field.

Topics Covered

Introduction

-- Obesity and Related Comorbidities

-- Mechanisms Underlying Food Intake and Obesity

-- Mechanisms Underlying Obesity-Related Comorbidities

-- Drugs to Treat Obesity

-- Investigational Obesity Drugs and Points of Drug Intervention

-- Obesity Platform-Based Drug Discovery Alliances

-- Directions in Obesity R&D

-- Outlook

-- Table 1. Select Targets That Regulate Appetite

-- Table 2. Select Obesity Drugs in Clinical Trials

-- Table 3. Select Drug Targets That Regulate Lipid Metabolism

-- Table 4. Select Drug Targets That Regulate Adipocytes or Their Signals

-- Table 5. Select Drug Discovery Alliances Targeting Obesity

-- Figure 1. Systems Involved with Controlling Appetite

-- Figure 2. Metabolic Pathways and Enzymes Involved in the Synthesis of Fat and Fatty Acids

Companies Mentioned

- Alizyme

- Amgen (from Tularik acquisition)

- Amylin Pharmaceuticals

- Arena Pharmaceuticals

- Merck

- Metabolic Pharmaceuticals

- Nastech Pharmaceuticals

- Peptimmune

- Regeneron

- Sanofi-Aventis

- Solvay/Bristol-Myers Squibb

For more information visit http://www.researchandmarkets.com/reports/c31682

Article

04-02-06, 02:24 AM	#1 (permalink)
Obesity Discussion Administrator Join Date: Jan 2005 Location: Phoenix, AZ Posts: 7,851 Weight Statistics 8/1/2006 Start Date: 185 lb Start Weight: 152 lb Current Weight: 155 lb Goal Weight: -33 lb Weight Loss: 5/1/2007 Goal Date:	Obesity Presents New Market Opportunities for Pharmaceutical Companies Obesity Presents New Market Opportunities for Pharmaceutical Companies 3/31/2006 11:45:00 AM EST Research and Markets (http://www.researchandmarkets.com/reports/c31682) has announced the addition of Obesity Drug Discovery: Success and Challenges for a New Pharmaceutical Market to their offering. Business Implications -- The prevalence of obesity has increased dramatically in the last ten years, prompting the Centers for Disease Control and Prevention to describe obesity as an epidemic. Obesity increases predisposition to various diseases, including diabetes, cardiovascular diseases, and cancer. In 2004, the United States Health and Human Services declared obesity to be a disease, creating important changes to Medicare and health care reimbursement policy for obesity-related therapies. -- Obesity has increasingly become the focus of major pharmaceutical companies as they recognize the potential for a new blockbuster market. Rimonabant, a drug that regulates appetite, is in Phase III clinical trials. Companies are also forming high-value alliances, including target and lead identification deals, with biotech companies for obesity drug discovery. -- Research into the causes of obesity has identified many potential targets and pathways that could be exploited to create novel therapies. New investigational obesity drugs and drug targets can be generally categorized into those that regulate appetite, lipid metabolism, and adipocytes or their signals. Obesity research is still in its infancy, and researchers are likely to identify many new potential targets and therapeutic approaches. -- Because obesity therapy is a preventive therapy for otherwise outwardly healthy people, patients and regulatory agencies will not tolerate unacceptable medium-to-long-term side effects. Companies must develop therapies with side effects that are not worse than the obesity-related comorbidities the drugs are trying to prevent. Another challenge for long-term obesity therapy is simply to overcome the evolutionary selection of multiple physiological and metabolic responses that favor appetite and fat storage. In recent years, obesity has become a major health problem for many postindustrial societies, so much so that in 2004, the United States Health and Human Services declared obesity to be a disease. Obesity poses a major health risk because it greatly increases the risk of comorbidities such as diabetes, cardiovascular diseases, arthritis, and cancer. Recognizing the potential for a new blockbuster market, major pharmaceutical companies have increasingly focused on obesity and its causes, in the process identifying many potential targets and pathways that could be exploited to create novel therapies. Studies on the molecular mechanisms involved in obesity are revealing a complex set of pathways, feedback loops, hormones, and metabolites that integrate multiple physiological systems in the brain, gastrointestinal system, endocrine system, and metabolic systems. The challenge for obesity drug discovery is that drugs must compete against powerful physiological and behavioral factors that have been selected by evolution to favor feeding and energy storage. In this Decision Resources report, we provide a detailed discussion of the mechanics of obesity and its comorbidities, as well as the targets and pathways identified as points of intervention by investigational obesity drugs. We will also examine directions being pursued in obesity research and development and corporate alliances and activities in the field. Topics Covered Introduction -- Obesity and Related Comorbidities -- Mechanisms Underlying Food Intake and Obesity -- Mechanisms Underlying Obesity-Related Comorbidities -- Drugs to Treat Obesity -- Investigational Obesity Drugs and Points of Drug Intervention -- Obesity Platform-Based Drug Discovery Alliances -- Directions in Obesity R&D -- Outlook -- Table 1. Select Targets That Regulate Appetite -- Table 2. Select Obesity Drugs in Clinical Trials -- Table 3. Select Drug Targets That Regulate Lipid Metabolism -- Table 4. Select Drug Targets That Regulate Adipocytes or Their Signals -- Table 5. Select Drug Discovery Alliances Targeting Obesity -- Figure 1. Systems Involved with Controlling Appetite -- Figure 2. Metabolic Pathways and Enzymes Involved in the Synthesis of Fat and Fatty Acids Companies Mentioned - Alizyme - Amgen (from Tularik acquisition) - Amylin Pharmaceuticals - Arena Pharmaceuticals - Merck - Metabolic Pharmaceuticals - Nastech Pharmaceuticals - Peptimmune - Regeneron - Sanofi-Aventis - Solvay/Bristol-Myers Squibb For more information visit http://www.researchandmarkets.com/reports/c31682 Article __________________